Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Janssen Research & Development, LLC
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07555938CT.gov Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | — | Recruiting | — | — | — |
NCT07428369CT.gov A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) | — | Withdrawn | — | — | — |
NCT07341867CT.gov Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | — | Not Yet Recruiting | — | — | — |
NCT07649525CT.gov Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level | — | Not Yet Recruiting | — | — | — |
NCT07452198CT.gov A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT07391657CT.gov A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | — | Recruiting | — | — | — |
NCT07095452CT.gov A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | — | Recruiting | — | — | — |
NCT07222761CT.gov A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Recruiting | — | — | — |
NCT06932562CT.gov A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | — | Recruiting | — | — | — |
NCT07107529CT.gov Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | — | Recruiting | — | — | — |
Show 144 more trialsShow fewer
NCT06827860CT.gov Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | — | Recruiting | — | — | — |
NCT06974786CT.gov Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | — | Recruiting | — | — | — |
NCT06953960CT.gov A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | — | Recruiting | — | — | — |
NCT07045909CT.gov Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) | — | Recruiting | — | — | — |
NCT06892522CT.gov A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | — | Recruiting | — | — | — |
NCT07015021CT.gov The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients | — | Not Yet Recruiting | — | — | — |
NCT06931704CT.gov Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) | — | Not Yet Recruiting | — | — | — |
NCT06785415CT.gov Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma | — | Recruiting | — | — | — |
NCT06615479CT.gov A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | — | Recruiting | — | — | — |
NCT06679101CT.gov A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | — | Recruiting | — | — | — |
NCT06768489CT.gov A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma | — | Recruiting | — | — | — |
NCT06413498CT.gov A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06577025CT.gov A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06353022CT.gov Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06505369CT.gov Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT06409702CT.gov Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | — | Recruiting | — | — | — |
NCT06232707CT.gov A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Withdrawn | — | — | — |
NCT06464991CT.gov A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) | — | Recruiting | — | — | — |
NCT06042725CT.gov MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | — | Recruiting | — | — | — |
NCT05896228CT.gov Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05572229CT.gov Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | — | Recruiting | — | — | — |
NCT06055075CT.gov A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT06119685CT.gov IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | — | Recruiting | — | — | — |
NCT06140966CT.gov Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05257083CT.gov A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05849610CT.gov Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05641324CT.gov A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | — | Terminated | — | — | — |
NCT05590377CT.gov A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT05434689CT.gov COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | — | Active Not Recruiting | — | — | — |
NCT05556616CT.gov A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma | — | Terminated | — | — | — |
NCT05527340CT.gov Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | — | Active Not Recruiting | — | — | — |
NCT05438043CT.gov A Study of Daratumumab | — | Recruiting | — | — | — |
NCT04756401CT.gov Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05695508CT.gov GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | — | Recruiting | — | — | — |
NCT05363111CT.gov Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05623020CT.gov A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | — | Recruiting | — | — | — |
NCT04933539CT.gov Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05552222CT.gov A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05259839CT.gov A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05581875CT.gov A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | — | Not Yet Recruiting | — | — | — |
NCT05455320CT.gov A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | — | Active Not Recruiting | — | — | — |
NCT05408026CT.gov Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | — | Withdrawn | — | — | — |
NCT05497804CT.gov Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | — | Active Not Recruiting | — | — | — |
NCT05137054CT.gov A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | — | Recruiting | — | — | — |
NCT05392946CT.gov Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | — | Active Not Recruiting | — | — | — |
NCT04975997CT.gov Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT05308654CT.gov A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | — | Active Not Recruiting | — | — | — |
NCT04700176CT.gov A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT05243342CT.gov A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT05280275CT.gov A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | — | Unknown | — | — | — |
NCT04895410CT.gov Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma | — | Terminated | — | — | — |
NCT04667663CT.gov CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. | — | Active Not Recruiting | — | — | — |
NCT04223661CT.gov Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | — | Withdrawn | — | — | — |
NCT04925193CT.gov Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05182073CT.gov FT576 in Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT04892446CT.gov Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT05083169CT.gov A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05020236CT.gov A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | — | Recruiting | — | — | — |
NCT04973605CT.gov A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | — | Recruiting | — | — | — |
NCT04782687CT.gov Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06868667CT.gov Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06868654CT.gov China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04910568CT.gov A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04892264CT.gov Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | — | Terminated | — | — | — |
NCT04661137CT.gov A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | — | Suspended | — | — | — |
NCT04722146CT.gov A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04824794CT.gov GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | — | Terminated | — | — | — |
NCT04649060CT.gov Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT04407442CT.gov Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab | — | Terminated | — | — | — |
NCT04614636CT.gov FT538 in Subjects With Advanced Hematologic Malignancies | — | Terminated | — | — | — |
NCT03841565CT.gov Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT04181827CT.gov A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04176718CT.gov Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM | — | Active Not Recruiting | — | — | — |
NCT04352205CT.gov Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | — | Terminated | — | — | — |
NCT04246047CT.gov Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04108195CT.gov A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04280328CT.gov Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04268498CT.gov A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04133636CT.gov A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04052880CT.gov Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | — | Active Not Recruiting | — | — | — |
NCT04136756CT.gov NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03989414CT.gov A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | — | Active Not Recruiting | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT03606577CT.gov An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT03942224CT.gov Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04124497CT.gov A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT03651128CT.gov Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT03500445CT.gov Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03701321CT.gov Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03763162CT.gov Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03829371CT.gov STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | — | Active Not Recruiting | — | — | — |
NCT03669445CT.gov Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma | — | Unknown | — | — | — |
NCT03710603CT.gov Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03742297CT.gov Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | — | Active Not Recruiting | — | — | — |
NCT03589222CT.gov SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03556332CT.gov A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation | — | Active Not Recruiting | — | — | — |
NCT04065789CT.gov Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | — | Completed | — | — | — |
NCT03412565CT.gov A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | — | Completed | — | — | — |
NCT03481556CT.gov Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM | — | Terminated | — | — | — |
NCT03314181CT.gov A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03439293CT.gov A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | — | Completed | — | — | — |
NCT03234972CT.gov A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03217812CT.gov A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) | — | Completed | — | — | — |
NCT03357952CT.gov A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03290950CT.gov A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03221634CT.gov Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | — | Withdrawn | — | — | — |
NCT03004287CT.gov 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | — | Active Not Recruiting | — | — | — |
NCT03068351CT.gov Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma | — | Completed | — | — | — |
NCT03180736CT.gov Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex | — | Completed | — | — | — |
NCT03158688CT.gov Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. | — | Completed | — | — | — |
NCT03012880CT.gov Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT03000452CT.gov A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | — | Completed | — | — | — |
NCT02773030CT.gov A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02807454CT.gov A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT02693535CT.gov TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | — | Recruiting | — | — | — |
NCT02343042CT.gov Selinexor and Backbone Treatments of Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT02541383CT.gov A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT02431208CT.gov A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT02393248CT.gov Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | — | Terminated | — | — | — |
NCT02136134CT.gov Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02128230CT.gov UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | — | Terminated | — | — | — |
NCT01946477CT.gov Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting | — | Completed | — | — | — |
NCT01998971CT.gov A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01849783CT.gov Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01665794CT.gov Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01592370CT.gov An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01548573CT.gov Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | — | Terminated | — | — | — |
NCT01415882CT.gov Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | — | Completed | — | — | — |
NCT01326702CT.gov Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | — | Completed | — | — | — |
NCT01055301CT.gov S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT00871013CT.gov Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy | — | Active Not Recruiting | — | — | — |
NCT00869232CT.gov UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | — | Active Not Recruiting | — | — | — |
NCT00734877CT.gov UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | — | Active Not Recruiting | — | — | — |
NCT00670631CT.gov Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment | — | Completed | — | — | — |
NCT00577512CT.gov 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE | — | Completed | — | — | — |
NCT00572169CT.gov UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | — | Active Not Recruiting | — | — | — |
NCT00574080CT.gov UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | — | Terminated | — | — | — |
NCT00577096CT.gov Effects of Exercise in Combination With Epoetin Alfa | — | Completed | — | — | — |
NCT00083915CT.gov DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | — | Completed | — | — | — |
NCT00083538CT.gov Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally | — | Completed | — | — | — |
NCT00005834CT.gov S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00004903CT.gov Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | — | Unknown | — | — | — |
NCT00083551CT.gov UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | — | Completed | — | — | — |
NCT00083681CT.gov DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Janssen Research & Development, LLC | Approved | BB · 70 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →